ImmunityBio (NASDAQ: IBRX)
$2.42
(-5.5%)
-$0.14
Price as of January 10, 2025, 4:00 p.m. ET
ImmunityBio Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
ImmunityBio Company Info
ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.
News & Analysis
Featured Article
Why Shares of ImmunityBio Jumped This Week
The company's founder is spending his own money to help finance the business's efforts.
Jim Halley | Sep 15, 2023
Featured Article
Why Shares of ImmunityBio Were Up on Wednesday
The company announced progress in two clinical trials.
Jim Halley | Jul 19, 2023
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.